Oral Silibinin Inhibits In vivo Human Bladder Tumor Xenograft Growth Involving Down-Regulation of Survivin

Purpose: Chemoprevention is an upcoming approach to control bladder cancer, which is one of the commonly diagnosed malignancies showing recurrence rate of 70% or even higher. Recently, we observed the in vitro efficacy of silibinin, a flavanolignan, in human bladder transitional cell papilloma RT4 cells. Here, we investigated the antitumor efficacy and associated mechanisms of silibinin in RT4 tumor xenograft. Experimental Design: RT4 tumor xenograft was implanted s.c. in athymic nude mice, and then animals were oral gavaged with silibinin at 100 and 200 mg/kg doses, 5 days/week for 12 weeks. Tumor growth, body weight, and diet consumption were recorded, and tumors were analyzed for proliferation, apoptosis, and angiogenesis biomarkers and molecular alterations by immunohistochemistry, immunoblot analysis, and ELISA. p53 small interfering RNA was used in cell culture to examine the role of p53 in survivin expression. Results: Silibinin feeding inhibited tumor xenograft growth without any gross signs of toxicity. Silibinin decreased tumor volume by 51% to 58% (P ≤ 0.01) and tumor weight by 44% to 49% (P < 0.05). Silibinin moderately (P < 0.001) decreased cell proliferation and microvessel density and strongly (P < 0.001) increased apoptosis in tumors. Silibinin robustly decreased survivin protein expression and its nuclear localization, as well as tumor-secreted level in mouse plasma, but increased p53 and cleaved caspase-3 levels in tumors. Silibinin-caused decrease in survivin was independent of p53. Conclusion: These findings identified in vivo antitumor efficacy of silibinin against human bladder tumor cells involving down-regulation of survivin and an increase in p53 expression together with enhanced apoptosis.

[1]  H. Grossman,et al.  Chemoprevention of bladder cancer , 2008, BJU international.

[2]  C. Shun,et al.  Stopping smoking might reduce tumour recurrence in nonmuscle‐invasive bladder cancer , 2007, BJU international.

[3]  M. Duffy,et al.  Survivin: a promising tumor biomarker. , 2007, Cancer letters.

[4]  R. Agarwal,et al.  Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. , 2007, Cancer research.

[5]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Stein,et al.  Superficial bladder cancer: part 1. Update on etiology, classification and natural history , 2006, Expert review of anticancer therapy.

[7]  R. Agarwal,et al.  Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. , 2006, Carcinogenesis.

[8]  R. Agarwal,et al.  A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients , 2006, Investigational New Drugs.

[9]  H. Zeng,et al.  Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder , 2006, Modern Pathology.

[10]  L. Dwyer-Nield,et al.  Effect of silibinin on the growth and progression of primary lung tumors in mice. , 2006, Journal of the National Cancer Institute.

[11]  D. Swinkels,et al.  Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[12]  Jian Yu,et al.  The transcriptional targets of p53 in apoptosis control. , 2005, Biochemical and biophysical research communications.

[13]  R. Agarwal,et al.  Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-κB: implications for angioprevention and antiangiogenic therapy , 2005, Oncogene.

[14]  R. Agarwal,et al.  Oral Silibinin Inhibits Lung Tumor Growth in Athymic Nude Mice and Forms a Novel Chemocombination with Doxorubicin Targeting Nuclear Factor κB–Mediated Inducible Chemoresistance , 2004, Clinical Cancer Research.

[15]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[16]  R. Agarwal,et al.  Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. , 2004, Carcinogenesis.

[17]  D. Hallahan,et al.  Survivin as a therapeutic target for radiation sensitization in lung cancer. , 2004, Cancer research.

[18]  C. Kwak,et al.  Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. , 2004, The Journal of urology.

[19]  R. Agarwal,et al.  Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. , 2003, Biochemical and biophysical research communications.

[20]  D. Altieri.  Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.

[21]  R. Agarwal,et al.  Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells , 2003, Oncogene.

[22]  R. Agarwal,et al.  Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  Matthias Dobbelstein,et al.  p21/CDKN1A Mediates Negative Regulation of Transcription by p53* , 2003, Journal of Biological Chemistry.

[24]  N. Socci,et al.  Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. , 2002, Cancer research.

[25]  Takuji Tanaka,et al.  Chemopreventive Effects of a Flavonoid Antioxidant Silymarin on N‐Butyl‐N‐(4‐ hydroxybutyl)nitrosamine‐induced Urinary Bladder Carcinogenesis in Male ICR Mice , 2002, Japanese journal of cancer research : Gann.

[26]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[27]  H. J. Kim,et al.  An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.

[28]  R. Hurst,et al.  Complexity, retinoid-responsive gene networks, and bladder carcinogenesis. , 1999, Advances in experimental medicine and biology.

[29]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[31]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[32]  L. Ellwein,et al.  Use of cell proliferation data in modeling urinary bladder carcinogenesis. , 1993, Environmental health perspectives.

[33]  H. Mascher,et al.  Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[34]  Y. Sekido,et al.  Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .

[35]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[36]  S. Ziaee,et al.  Diagnosis of bladder cancer by urine survivin, an inhibitor of apoptosis: a preliminary report. , 2006, Urology journal.

[37]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[38]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.